The Wild West of the OTC playground. No 10-k, no 10-q, no speak. Yet lots of effort to set up OSA program in Australia and “remarkable” progress with their pain/epilepsy candidate in all kinds of preclinicals and robust NIH trials and only a few dozen message forum posters even are remotely interested…
A measly $600k+ valuation for all the effort and pharma science to help patients with unmet needs. I suppose being under appreciated would make me mad too..
Logic will probably dictate course correction or not….